Staphylococcus aureus is a Gram-positive toxin-forming bacterium that is a widespread human commensal and pathogen.
Approximately 30-60% of the population is colonized either permanently or intermittently.
S.aureus (SA) is responsible for a wide range of clinical syndromes ranging from high mortality blood stream infections (BSIs) to community-based skin and soft tissue infections such as skin abscesses (SSTIs).
SA is a common cause of healthcare-associated infections (HAIs) such as pneumonia and surgical site infections (SSIs).
An antibiotic resistant form of S.aureus (MRSA) has become a major problem both in and out of the hospital with an estimated ~88-90K infections occurring in the USA each year with substantial economic burden.
SA vaccines which prevent and/or reduce the impact of SA infections are greatly needed although it is becoming accepted that a universal vaccine to impact upon all infection types and reduce colonization is an optimistic goal.
Development has been thwarted with numerous failures. Recently, Pfizer vaccines were developing SA4Ag, a multicomponent vaccine (reached Phase IIb, fast track designation) to address SA BSI and SSIs in surgical patients undergoing elective open posterior spinal fusion procedures.
This MarketVIEW product consists of a detailed Executive presentation (~195 .pdf slides) and comprehensive MS-Excel workbook (.xls) which forecast the potential commercial value of a S.aureus “healthcare-associated” vaccine to target BSIs and SSIs in US surgical and End-stage renal disease patients (ESRD) in the US to 2030. For surgery patients, there is a sophisticated uptake methodology whereby specific surgical procedures are assigned a priority level along with an assessment of US state (group of) HO-MRSA risk. Efforts have been made to account for complex overlapping datasets so that discrete numbers of procedures can be forecast as eligible vaccine populations. The analysis also provides a detailed review of latest S.aureus (MRSA) US epidemiology (EIP, NHSN) , prevention/legislative efforts (HHS Action Plan), vaccinology and current R&D approaches/activity. MarketVIEW: Staphylococcus aureus BSI/SSI vaccine (USA) lays a solid groundwork designed to initiate or challenge any internal client assessment of this exciting but challenging commercial opportunity.
MarketVIEW: Staphylococcus aureus BSI/SSI vaccine (USA) lays a firm groundwork designed to initiate or challenge any internal client assessment of this exciting but challenging commercial opportunity.
THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf, 195 slides) + 1 MODEL (.xls, 55 worksheets)
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.